Study of HQP1351 in Subjects With Refractory Chronic Myeloid Leukemia

Complete Title: A Phase Ib Study of the Pharmacokinetics, Safety And Efficacy of Orally Administered HQP1351 in Subjects with Refractory Chronic Myeloid Leukemia (CML) AND PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL)
Trial Phase: I
Investigator: Oehler, Vivian, G

A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with CML CP and AP, who have experienced resistance or intolerance to at least two tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, dasatinib, bosutinib or ponatinib.

Look up Trial at NIH
Keywords:
  • Leukemia, Chronic Myeloid (CML); Leukemia, Myeloid
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Checklist icon

Join a Clinical Trial

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Patient Guide to Clinical Trials

Contact Us

If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.

Request an Appointment